Last reviewed · How we verify

NCT03612388: MiECC

Combined Use of a Novel Cardioplegic Formula With Myocardial Protection System (MPS)® Versus Cardioplexol ® in Isolated Coronary Artery Bypass Grafting (CABG) Using MiECC;

Completed Last updated 31 July 2019
What this trial tests

trial testing use of a cardioplegic formula in isolated CABG (coronary artery bypass grafting) using MiECC (Minimal extracorporeal circulation in Complication of Extracorporeal Circulation in 211 participants. Completed in 13 March 2019.

Timeline
28 February 2010
Primary endpoint
31 March 2018
13 March 2019

Quick facts

Lead sponsorUniversity Hospital, Basel, Switzerland
StatusCompleted
Study typeOBSERVATIONAL
Enrollment211
Start date28 February 2010
Primary completion31 March 2018
Estimated completion13 March 2019
Sites1 location across Switzerland

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Basel, Switzerland

Who can join

Eligibility, any sex, with Complication of Extracorporeal Circulation or Complication of Coronary Artery Bypass Graft. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Combined use of a novel cardioplegic formula with MPS® (Myocardial protection system) versus Cardioplexol ® (colloid solution with Procaine, magnesium and potassium) in isolated CABG (coronary artery bypass grafting) using MiECC (Minimal extracorporeal circulation system).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other University Hospital, Basel, Switzerland trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03612388.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing